Anavex Life Sciences Corp. (AVXL)
NASDAQ: AVXL · Real-Time Price · USD
4.400
-0.050 (-1.12%)
At close: Dec 5, 2025, 4:00 PM EST
4.440
+0.040 (0.91%)
After-hours: Dec 5, 2025, 7:51 PM EST
Anavex Life Sciences Employees
Anavex Life Sciences had 34 employees as of September 30, 2025. The number of employees decreased by 8 or -19.05% compared to the previous year.
Employees
34
Change (1Y)
-8
Growth (1Y)
-19.05%
Revenue / Employee
n/a
Profits / Employee
-$1,364,029
Market Cap
393.13M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AVXL News
- 2 days ago - AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm - Business Wire
- 10 days ago - Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference - GlobeNewsWire
- 11 days ago - Anavex Life Sciences Corp. (AVXL) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 17 days ago - Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference - GlobeNewsWire
- 18 days ago - Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025 - GlobeNewsWire
- 22 days ago - Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease - GlobeNewsWire
- 5 weeks ago - Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Control Group - GlobeNewsWire